Search results for: 'engineering service'

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

05 Jun 2018  |  Global  |  Market Research

Anti-Aging Therapies and Services Market—Trends and Growth Opportunities, Forecast to 2022

Focus on Integrative Solutions Combining Dietary Supplements and Aesthetic Solutions with Clinical Therapeutics as the Market Moves Toward a ‘Prevent-Manage-Repair’ Continuum

Infographics

×

Key Issues Addressed

The rapidly aging global population is placing immense pressure on healthcare systems across countries and regions. The improvement in life expectancy levels has created a large cohort of aged patients who suffer from one or more chronic diseases. Traditionally, the approach towards the management of this issue has been on ‘repair’, i.e., treatment...

RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...

05 Sep 2022  |  Global  |  Technology Research

Technology Growth Opportunities for Exosome-Mediated Drug Delivery

Exosomes Are Promising Delivery Carriers for Advanced Therapeutics

Infographics

×

Exosome-mediated drug delivery is a promising alternative to conventional drug delivery methods, making rapid strides in the biopharmaceutical industry because of the safety and efficacy advantages exosomes offer as nanocarriers over synthetic nanoparticles. The widely explored concepts of nanomedicine, nucleic acid therapeutics, and cell-free vacc...

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process developm...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...